UNSPSC 51111855: Lanreotide

This classification denotes a somatostatin receptor agonist with the molecular formula C54H69N11O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3DE8943Y, chemically known as l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide but generally known as lanreotide, which bears US NIH Compound Identifier 71349. European Medicines Agency schedules Lanreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08402MIG.

UNSPSC 51111855 Lanreotide, a Commodity code, encompasses pharmaceutical products procured through state and local cooperative purchasing agreements to supply government facilities, schools, and healthcare systems. State and local buyers use this code to source branded and generic pharmaceuticals, including specialty injectable medications like lanreotide, through established supply chains that rely on authorized wholesalers and direct manufacturer relationships. The work involves establishing contracts with pharmaceutical manufacturers who commit to stable pricing, regulatory compliance, and reliable supply to member jurisdictions within cooperative purchasing alliances.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities including Oregon. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates cGMP certification, Drug Supply Chain Security Act compliance, contractual relationships with at least two of the three wholesalers, and comprehensive insurance including $5 million commercial general liability coverage. Pricing is weighted at 75 percent of the evaluation, with vendors selecting from flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures; the contract term runs two years for new vendors with optional MMCAP extensions, while incumbent responders' agreements extend through June 30, 2028. All products must be available in the marketplace by May 15, 2026, with the awarded contracts effective July 1, 2026.